Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H9C1
UPID:
SPE39_HUMAN
Alternative names:
VPS33B-interacting protein in apical-basolateral polarity regulator; VPS33B-interacting protein in polarity and apical restriction
Alternative UPACC:
Q9H9C1; B4DPI6; O95434; Q9H7E1; Q9H9I9
Background:
Spermatogenesis-defective protein 39 homolog, also known as VPS33B-interacting protein, plays a crucial role in endosomal maturation, vesicular trafficking, and maintenance of apical-basolateral polarity. It is involved in the VPS33B:VIPAS39 complex, influencing epithelial cell recycling pathways and lysosomal trafficking, independent of VPS33B.
Therapeutic significance:
The protein's malfunction is linked to Arthrogryposis, renal dysfunction, and cholestasis syndrome 2, a multisystem disorder. Understanding its role could lead to novel therapeutic strategies for this and potentially other related diseases.